AZ, Daiichi roll out Japanese iPhone app; India's Natco aims big with Copaxone copy; NICE backs bladder drug Enablex;

@FiercePharma: Aging population to fuel big leap in cancer cases--and drug sales. Can research keep up? ICYMI yesterday | Follow @FiercePharma

@EricPFierce: FDA warning letter for Stride's Agila plant was overshadowed by Ranbaxy's news of third import alert. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Reps making fewer hospital visits; one tells the work lull has him "spending more time drinking tea and worrying about redundancy." | Follow @CarlyHFierce

[No ads for editors]

> AstraZeneca ($AZN) and Daiichi Sankyo rolled out an iPhone app, available only in Japanese, designed to educate patients about acid reflux and esophagitis; the two companies co-promote the stomach drug Nexium in Japan. Report

> Natco Pharma's proposed copy of the Teva Pharmaceutical Industries ($TEVA) multiple sclerosis drug Copaxone could dramatically boost its fortunes, but only if the drug wins FDA approval. Report

> The U.K.'s National Institute for Health and Care Excellence (NICE) backed Warner Chilcott's ($WCRX) Enablex (darifenacin) for urinary incontinence in women with overactive bladder. Report

> Toronto-based Axxess Pharma agreed to buy the assets of OTC healthcare company Revive Biosciences, including a best-selling pain reliever. Report (sub. req.)

> A member of parliament in the U.K. is supporting an inquiry into the availability of cutting-edge drugs for rare diseases. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Special Report: 'Big' med tech M&A deals getting smaller. Feature | Follow @FierceMedDev

@DamianFierce: Feisty company says Covidien willfully violated its patents, sues for injunction and cash. Story | Follow @DamianFierce

@MarkHFierce: Doctor-owned MRI facilities may be overused, a new study concludes. Article | Follow @MarkHFierce

@MichaelGFierce: Special report from FierceDrugDelivery: The race for the artificial pancreas. Report | Follow @MichaelGFierce

> Sonitus snags $10M to market hearing device. Story

> Natera heads east for prenatal Dx market expansion. More

Biotech News

@FierceBiotech: Next FierceBiotech Event: 'Big Data Gets Smart.' More | Register | Follow @FierceBiotech

@JohnCFierce: In case you missed it, this is why ChemoCentryx got back the rights to vercirnon. Article | Follow @JohnCFierce

@EmilyMFierce: CDC Threat Report: Yes, Agricultural Antibiotics Play a Role in Drug Resistance. Wired report | Follow @EmilyMFierce

> Abandoned by GlaxoSmithKline, ChemoCentryx will try again on troubled Crohn's drug. Story

> Aerie Pharma jumps into IPO game with $58M pitch to investors. News

> Can AstraZeneca change a narrative of R&D retreat and defeat? More

> Report: Clovis looks to cash in on the bull market for biotechs. Article

Biomarkers News

> Study: Change in breast cancer biomarker indicates recurrence-free survival. More

> 'Better' lung cancer biomarker could aid early detection. More

> 12-year study flags new biomarker for high risk of diabetes. Story

> Three-gene biomarker could detect aggressive prostate cancer sooner. Article

> RAS mutations predict lack of response to Vectibix. Item

Drug Delivery News

> Drug delivery patch mimics adhesion used by beetles. More

> Mystic scores two platform patents for intraocular, intranasal delivery. Article

> Veritas wins European patent for RNA delivery method. Item

> Profectus begins PhI HIV vax trial with 'prime-boost' delivery. Story

> Microbottles with dissolving 'corks' deliver drugs in higher temps. Report

Diagnostics News

> Medicare Dx payment reform tackled in U.S. House bill. Article

> Adaptive Biotechnologies wins NIH backing for immune system Dx test. Story

> Doctors may be overusing MRI facilities they own. Report

> Canadian startup's analyzer could upend HIV, cancer Dx testing. Article

> International team builds 2 rapid tests for malaria treatment resistance. More

And Finally... Patients worry that prescription drug coverage under the new healthcare law might cost them more money. Report (sub. req.)

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."